SAN DIEGO, Calif.--Aurora Biosciences and Acacia Biosciences announced that they have agreed to settle an intellectual property dispute by cross-licensing key genomic technologies. Under the agreement, Aurora licensed certain elements of its patented fluorescent protein technology to Acacia, and Acacia licensed elements of its Genome Reporter Matrix technology to Aurora. Aurora also withdrew a patent infringement suit filed against, but not yet served on, Acacia, and Acacia agreed not to challenge the validity or enforceability of the Aurora patents regarding the licensed fluorescent proteins.
Acacia's President and CEO, Bruce Cohen, called the cross-licensing agreement a "useful commercial step for the two companies and a critical milestone for the genomics industry." Cohen added that the agreement "sends a signal to collaborators and investors that biotechnology companies that are active in genomic research and drug discovery can resolve intellectual property differences in a productive manner that does not impair the ability to advance scientific and business objectives."